Disopyramide

Generic name: Pronounced as (dye soe peer' a mide)
Brand names
  • Norpace®
  • Norpace® CR
Click on drug name to hear pronunciation

Medical Content Reviewed By HelloPharmacist Staff

Last Revised - 07/15/2020

Taking antiarrhythmic drugs, including disopyramide, may increase the risk of death. Tell your doctor if you have heart disease such as a valve problem or heart failure (HF; condition in which the heart cannot pump enough blood to other parts of the body). If you experience any of the following symptoms, call your doctor immediately: irregular heartbeat or chest pain.

Talk to your doctor about the risks of taking disopyramide. Disopyramide may increase the chance of having arrhythmias (irregular heartbeats) and has not been proven to help people without life-threatening arrhythmias to live longer.

Disopyramide is used to treat certain types of irregular heartbeats). Disopyramide is in a class of medications called antiarrhythmic medications. It works by making your heart more resistant to abnormal activity.

Disopyramide comes as a capsule and an extended-release (long-acting) capsule to take by mouth. Disopyramide capsules may be taken every 6 or 8 hours. The extended-release capsule is usually taken every 12 hours. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take disopyramide exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.

Swallow the extended-release capsules; do not open, crush, or chew them.

Disopyramide helps control your condition but will not cure it. Continue to take disopyramide even if you feel well. Do not stop taking disopyramide without talking to your doctor.

This medication is sometimes prescribed for other uses; ask your doctor or pharmacist for more information.

Before taking disopyramide,

  • tell your doctor and pharmacist if you are allergic to disopyramide, any other medications, or any of the ingredients in disopyramide capsules. Ask your pharmacist for a list of the ingredients.

  • tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: clarithromycin, erythromycin (E.E.S., Eryc, Erythrocin, others), phenytoin (Dilantin, Phenytek), propranolol (Inderal, Innopran), and verapamil (Calan, Tarka, Verelan). Your doctor may need to change the doses of your medications or monitor you carefully for side effects.

  • tell your doctor if you have heart block (condition in which electrical signals are not passed normally from the upper chambers of the heart to the lower chambers) or have or have ever had a prolonged QT interval (condition that increases the risk of developing an irregular heartbeat that may cause fainting or sudden death). Your doctor may tell you not to take disopyramide.

  • tell your doctor if you have or have ever had heart disease, low or high blood levels of potassium in your blood, diabetes, glaucoma, myasthenia gravis (a disorder of the nervous system that causes muscle weakness), urinary retention, benign prostatic hypertrophy, kidney or liver disease.

  • tell your doctor if you are pregnant, plan to become pregnant, or are breastfeeding. If you become pregnant while taking disopyramide, call your doctor.

  • talk to your doctor about the risks and benefits of taking disopyramide if you are 65 years of age or older. Older adults should not usually take disopyramide because it is not as safe or effective as other medications that can be used to treat the same condition.

  • if you are having surgery, including dental surgery, tell the doctor or dentist that you are taking disopyramide.

  • ask your doctor about the safe use of alcoholic beverages while you are taking disopyramide. Alcohol can make the side effects from disopyramide worse.

Take the missed dose as soon as you remember it. However, if it is almost time for the next dose, skip the missed dose and continue your regular dosing schedule. Do not take a double dose to make up for a missed one.

  • Disopyramide may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:

    • dizziness or lightheadedness

    • difficult urination

    • frequent urination

    • dry mouth

    • constipation

    • blurred vision

    • nausea

    • fatigue

    • headache

    • weakness

    • stomach pain or bloating

    • fatigue

    • weakness

    • headache

    • rash

  • Some side effects can be serious. If you experience any of the following symptoms, call your doctor immediately:

    • chest pain

    • swelling of the feet or hands

    • unusual weight gain

    • irregular heartbeat

    • shortness of breath

    • sudden changes in mental status

  • If you experience a serious side effect, you or your doctor may send a report to the Food and Drug Administration's (FDA) MedWatch Adverse Event Reporting program online (http://www.fda.gov/Safety/MedWatch) or by phone (1-800-332-1088).

Keep this medication in the container it came in, tightly closed, and out of reach of children. Store it at room temperature and away from excess heat and moisture (not in the bathroom).

It is important to keep all medication out of sight and reach of children as many containers (such as weekly pill minders and those for eye drops, creams, patches, and inhalers) are not child-resistant and young children can open them easily. To protect young children from poisoning, always lock safety caps and immediately place the medication in a safe location – one that is up and away and out of their sight and reach. http://www.upandaway.org

Unneeded medications should be disposed of in special ways to ensure that pets, children, and other people cannot consume them. However, you should not flush this medication down the toilet. Instead, the best way to dispose of your medication is through a medicine take-back program. Talk to your pharmacist or contact your local garbage/recycling department to learn about take-back programs in your community. See the FDA's Safe Disposal of Medicines website (http://goo.gl/c4Rm4p) for more information if you do not have access to a take-back program.

In case of overdose, call the poison control helpline at 1-800-222-1222. Information is also available online at https://www.poisonhelp.org/help. If the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services at 911.

Symptoms of overdose may include:

  • slow or irregular heartbeat

  • dry mouth

  • difficulty urinating

  • constipation

  • loss of consciousness

Keep all appointments with your doctor and the laboratory. Your doctor will need to determine your response to disopyramide.

Do not let anyone else take your medication. Ask your pharmacist any questions you have about refilling your prescription.

It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies.

Drug Interaction
Moxifloxacin Moxifloxacin The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Disopyramide.
Repaglinide Repaglinide The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Repaglinide.
Insulin Glargine (rDNA origin) Injection Insulin Glargine (rDNA origin) Injection The risk or severity of hypoglycemia can be increased when Insulin glargine is combined with Disopyramide.
Leflunomide Leflunomide The serum concentration of Disopyramide can be decreased when it is combined with Leflunomide.
Nevirapine Nevirapine The metabolism of Disopyramide can be decreased when combined with Nevirapine.
Dolasetron Dolasetron The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Disopyramide.
Aminophylline Aminophylline The metabolism of Aminophylline can be decreased when combined with Disopyramide.
Anagrelide Anagrelide The risk or severity of QTc prolongation can be increased when Anagrelide is combined with Disopyramide.
Bisacodyl Bisacodyl The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Disopyramide.
Cilostazol Cilostazol The risk or severity of QTc prolongation can be increased when Cilostazol is combined with Disopyramide.
Clopidogrel Clopidogrel The metabolism of Clopidogrel can be decreased when combined with Disopyramide.
Diphenoxylate Diphenoxylate The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Disopyramide.
Erythromycin and Sulfisoxazole Erythromycin and Sulfisoxazole Erythromycin may increase the QTc-prolonging activities of Disopyramide.
Estrogen and Progestin (Oral Contraceptives) Estrogen and Progestin (Oral Contraceptives) The metabolism of Conjugated estrogens can be decreased when combined with Disopyramide.
Fenofibrate Fenofibrate Disopyramide may decrease the excretion rate of Fenofibrate which could result in a higher serum level.
Guanfacine Guanfacine Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Magnesium Hydroxide Magnesium Hydroxide Disopyramide may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.
Magnesium Oxide Magnesium Oxide The therapeutic efficacy of Magnesium oxide can be decreased when used in combination with Disopyramide.
Miglitol Miglitol The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Miglitol.
Mycophenolate Mycophenolate Disopyramide may decrease the excretion rate of Mycophenolic acid which could result in a higher serum level.
Naratriptan Naratriptan Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Olsalazine Olsalazine Olsalazine may increase the hypoglycemic activities of Disopyramide.
Paregoric Paregoric The risk or severity of adverse effects can be increased when Morphine is combined with Disopyramide.
Penbutolol Penbutolol Disopyramide may increase the bradycardic activities of Acebutolol.
Pentazocine Pentazocine The risk or severity of adverse effects can be increased when Pentazocine is combined with Disopyramide.
Polyethylene glycol-electrolyte solution (PEG-ES) Polyethylene glycol-electrolyte solution (PEG-ES) The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Disopyramide.
Potassium Potassium Potassium may increase the excretion rate of Disopyramide which could result in a lower serum level and potentially a reduction in efficacy.
Prednisone Prednisone The risk or severity of hyperglycemia can be increased when Prednisone is combined with Disopyramide.
Psyllium Psyllium The therapeutic efficacy of Plantago seed can be decreased when used in combination with Disopyramide.
Ranitidine Ranitidine The risk or severity of adverse effects can be increased when Disopyramide is combined with Ranitidine.
Reserpine Reserpine Reserpine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Rizatriptan Rizatriptan Disopyramide may increase the central nervous system depressant (CNS depressant) activities of Rizatriptan.
Sumatriptan Sumatriptan The therapeutic efficacy of Disopyramide can be increased when used in combination with Sumatriptan.
Tacrolimus Tacrolimus The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Disopyramide.
Tizanidine Tizanidine The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Disopyramide.
Triamcinolone Triamcinolone The risk or severity of hyperglycemia can be increased when Triamcinolone is combined with Disopyramide.
Zolmitriptan Zolmitriptan The metabolism of Zolmitriptan can be decreased when combined with Disopyramide.
Ampicillin Injection Ampicillin Injection Disopyramide may decrease the excretion rate of Ampicillin which could result in a higher serum level.
Doxycycline Injection Doxycycline Injection Doxycycline may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Famotidine Injection Famotidine Injection The risk or severity of QTc prolongation can be increased when Famotidine is combined with Disopyramide.
Fluconazole Injection Fluconazole Injection The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Fluconazole.
Foscarnet Injection Foscarnet Injection The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Disopyramide.
Hydromorphone Injection Hydromorphone Injection The risk or severity of adverse effects can be increased when Hydromorphone is combined with Disopyramide.
Interferon Beta-1b Injection Interferon Beta-1b Injection The metabolism of Disopyramide can be decreased when combined with Interferon beta-1b.
Interferon Gamma-1b Injection Interferon Gamma-1b Injection The metabolism of Disopyramide can be decreased when combined with Interferon gamma-1b.
Levofloxacin Injection Levofloxacin Injection The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Disopyramide.
Meperidine Injection Meperidine Injection The risk or severity of adverse effects can be increased when Meperidine is combined with Disopyramide.
Methylprednisolone Injection Methylprednisolone Injection The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Disopyramide.
Metoclopramide Injection Metoclopramide Injection The therapeutic efficacy of Disopyramide can be decreased when used in combination with Metoclopramide.
Metronidazole Injection Metronidazole Injection The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Disopyramide.
Morphine Injection Morphine Injection The risk or severity of adverse effects can be increased when Morphine is combined with Disopyramide.
Pamidronate Injection Pamidronate Injection Pamidronic acid may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Vancomycin Injection Vancomycin Injection Disopyramide may decrease the excretion rate of Vancomycin which could result in a higher serum level.
Altretamine Altretamine Amphetamine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Cefuroxime Cefuroxime Cefuroxime may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Cyclosporine Cyclosporine Cyclosporine may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Ondansetron Ondansetron The risk or severity of QTc prolongation can be increased when Ondansetron is combined with Disopyramide.
Granisetron Granisetron The risk or severity of QTc prolongation can be increased when Granisetron is combined with Disopyramide.
Torsemide Torsemide The therapeutic efficacy of Disopyramide can be increased when used in combination with Torasemide.
Olanzapine Olanzapine The risk or severity of QTc prolongation can be increased when Olanzapine is combined with Disopyramide.
Alosetron Alosetron The metabolism of Disopyramide can be decreased when combined with Alosetron.
Dofetilide Dofetilide Dofetilide may increase the arrhythmogenic activities of Disopyramide.
Entacapone Entacapone Entacapone may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Hydroxychloroquine Hydroxychloroquine The therapeutic efficacy of Disopyramide can be increased when used in combination with Hydroxychloroquine.
Meloxicam Meloxicam Meloxicam may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Oxcarbazepine Oxcarbazepine Oxcarbazepine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Pantoprazole Pantoprazole Pantoprazole may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Temozolomide Temozolomide Disopyramide may decrease the excretion rate of Temozolomide which could result in a higher serum level.
Zaleplon Zaleplon Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Anakinra Anakinra The metabolism of Disopyramide can be increased when combined with Anakinra.
Desloratadine Desloratadine The risk or severity of QTc prolongation can be increased when Desloratadine is combined with Disopyramide.
Linezolid Linezolid Linezolid may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Rivastigmine Rivastigmine The therapeutic efficacy of Disopyramide can be decreased when used in combination with Rivastigmine.
Trimipramine Trimipramine The risk or severity of QTc prolongation can be increased when Trimipramine is combined with Disopyramide.
Etanercept Injection Etanercept Injection The metabolism of Disopyramide can be increased when combined with Etanercept.
Glycopyrrolate Glycopyrrolate The risk or severity of adverse effects can be increased when Disopyramide is combined with Glycopyrronium.
Modafinil Modafinil The metabolism of Disopyramide can be increased when combined with Armodafinil.
Perindopril Perindopril Disopyramide may decrease the excretion rate of Perindopril which could result in a higher serum level.
Tenofovir Tenofovir Tenofovir may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Choline Magnesium Trisalicylate Choline Magnesium Trisalicylate Choline magnesium trisalicylate may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Sirolimus Sirolimus Sirolimus may increase the QTc-prolonging activities of Disopyramide.
Epinephrine Injection Epinephrine Injection The therapeutic efficacy of Disopyramide can be decreased when used in combination with Epinephrine.
Eplerenone Eplerenone Eplerenone may increase the excretion rate of Disopyramide which could result in a lower serum level and potentially a reduction in efficacy.
Escitalopram Escitalopram The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Escitalopram.
Zonisamide Zonisamide Zonisamide may increase the arrhythmogenic activities of Disopyramide.
Adalimumab Injection Adalimumab Injection The metabolism of Disopyramide can be increased when combined with Adalimumab.
Aripiprazole Aripiprazole The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Disopyramide.
Atomoxetine Atomoxetine The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Disopyramide.
Dexmethylphenidate Dexmethylphenidate Dexmethylphenidate may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Atazanavir Atazanavir The risk or severity of QTc prolongation can be increased when Atazanavir is combined with Disopyramide.
Almotriptan Almotriptan Disopyramide may increase the central nervous system depressant (CNS depressant) activities of Almotriptan.
Eletriptan Eletriptan Eletriptan may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Mefloquine Mefloquine The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Disopyramide.
Polyethylene Glycol 3350 Polyethylene Glycol 3350 The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Disopyramide.
Rosuvastatin Rosuvastatin The therapeutic efficacy of Disopyramide can be increased when used in combination with Rosuvastatin.
Vardenafil Vardenafil The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Disopyramide.
Alfuzosin Alfuzosin The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Disopyramide.
Emtricitabine Emtricitabine Disopyramide may decrease the excretion rate of Emtricitabine which could result in a higher serum level.
Interferon Beta-1a Subcutaneous Injection Interferon Beta-1a Subcutaneous Injection The metabolism of Disopyramide can be decreased when combined with Interferon beta-1a.
Memantine Memantine The serum concentration of Disopyramide can be increased when it is combined with Memantine.
Tegaserod Tegaserod The metabolism of Tegaserod can be decreased when combined with Disopyramide.
Tadalafil Tadalafil Disopyramide may decrease the excretion rate of Tadalafil which could result in a higher serum level.
Fosamprenavir Fosamprenavir The therapeutic efficacy of Disopyramide can be decreased when used in combination with Fosamprenavir.
Frovatriptan Frovatriptan The metabolism of Frovatriptan can be decreased when combined with Disopyramide.
Gemifloxacin Gemifloxacin The risk or severity of QTc prolongation can be increased when Gemifloxacin is combined with Disopyramide.
Progesterone Progesterone The therapeutic efficacy of Disopyramide can be decreased when used in combination with Progesterone.
Apomorphine Injection Apomorphine Injection The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Disopyramide.
Infliximab Injection Infliximab Injection The metabolism of Disopyramide can be increased when combined with Infliximab.
Oxandrolone Oxandrolone Oxandrolone may increase the hypoglycemic activities of Disopyramide.
Protriptyline Protriptyline The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Disopyramide.
Duloxetine Duloxetine The metabolism of Duloxetine can be decreased when combined with Disopyramide.
Norethindrone Norethindrone The therapeutic efficacy of Disopyramide can be decreased when used in combination with Norethisterone.
Tinidazole Tinidazole Disopyramide may decrease the excretion rate of Tinidazole which could result in a higher serum level.
Trospium Trospium The risk or severity of adverse effects can be increased when Trospium is combined with Disopyramide.
Bosentan Bosentan The therapeutic efficacy of Disopyramide can be increased when used in combination with Bosentan.
Cefditoren Cefditoren Disopyramide may decrease the excretion rate of Cefdinir which could result in a higher serum level.
Cinacalcet Cinacalcet The metabolism of Cinacalcet can be decreased when combined with Disopyramide.
Cyanocobalamin Injection Cyanocobalamin Injection Hydroxocobalamin may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Erlotinib Erlotinib The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Erlotinib.
Eszopiclone Eszopiclone Eszopiclone may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Ganciclovir Ganciclovir The risk or severity of adverse effects can be increased when Disopyramide is combined with Ganciclovir.
Insulin Aspart (rDNA Origin) Injection Insulin Aspart (rDNA Origin) Injection The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Insulin aspart.
Ribavirin Ribavirin Disopyramide may decrease the excretion rate of Ribavirin which could result in a higher serum level.
Solifenacin Solifenacin The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Disopyramide.
Valganciclovir Valganciclovir Disopyramide may decrease the excretion rate of Valganciclovir which could result in a higher serum level.
Voriconazole Voriconazole The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Disopyramide.
Adefovir Adefovir Adefovir may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Dextroamphetamine Dextroamphetamine Amphetamine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Entecavir Entecavir The metabolism of Entecavir can be decreased when combined with Disopyramide.
Peginterferon Alfa-2a Injection Peginterferon Alfa-2a Injection The metabolism of Disopyramide can be decreased when combined with Peginterferon alfa-2a.
Peginterferon Alfa-2b (PEG-Intron) Peginterferon Alfa-2b (PEG-Intron) The serum concentration of Disopyramide can be increased when it is combined with Peginterferon alfa-2b.
Pramlintide Injection Pramlintide Injection The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Disopyramide.
Sodium Oxybate Sodium Oxybate Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Exenatide Injection Exenatide Injection The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Exenatide.
Ibandronate Ibandronate The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Disopyramide.
Isocarboxazid Isocarboxazid Isocarboxazid may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Ramelteon Ramelteon The metabolism of Ramelteon can be decreased when combined with Disopyramide.
Darifenacin Darifenacin The risk or severity of adverse effects can be increased when Disopyramide is combined with Darifenacin.
Fentanyl Fentanyl The risk or severity of adverse effects can be increased when Disopyramide is combined with Fentanyl.
Pregabalin Pregabalin Pregabalin may increase the arrhythmogenic activities of Disopyramide.
Deferasirox Deferasirox The serum concentration of Disopyramide can be increased when it is combined with Deferasirox.
Phenylephrine Phenylephrine The metabolism of Disopyramide can be increased when combined with Phenylephrine.
Tipranavir Tipranavir The therapeutic efficacy of Disopyramide can be decreased when used in combination with Tipranavir.
Felbamate Felbamate The risk or severity of QTc prolongation can be increased when Felbamate is combined with Disopyramide.
Insulin Detemir (rDNA Origin) Injection Insulin Detemir (rDNA Origin) Injection The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Insulin detemir.
Ranolazine Ranolazine The risk or severity of QTc prolongation can be increased when Ranolazine is combined with Disopyramide.
Abatacept Injection Abatacept Injection The metabolism of Disopyramide can be increased when combined with Abatacept.
Rasagiline Rasagiline The metabolism of Rasagiline can be decreased when combined with Disopyramide.
Imatinib Imatinib The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Imatinib.
Sitagliptin Sitagliptin The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Sitagliptin.
Varenicline Varenicline The excretion of Varenicline can be decreased when combined with Disopyramide.
Albuterol Albuterol The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Disopyramide.
Paliperidone Paliperidone The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Paliperidone.
Bortezomib Bortezomib The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Disopyramide.
Clofarabine Injection Clofarabine Injection The serum concentration of Clofarabine can be increased when it is combined with Disopyramide.
Insulin Glulisine (rDNA origin) Injection Insulin Glulisine (rDNA origin) Injection The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Insulin glulisine.
Lubiprostone Lubiprostone Disopyramide may decrease the excretion rate of Lubiprostone which could result in a higher serum level.
Oxaliplatin Injection Oxaliplatin Injection The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Disopyramide.
Posaconazole Posaconazole The risk or severity of QTc prolongation can be increased when Posaconazole is combined with Disopyramide.
Primaquine Primaquine The risk or severity of QTc prolongation can be increased when Primaquine is combined with Disopyramide.
Bismuth Subsalicylate Bismuth Subsalicylate Bismuth subsalicylate may increase the hypoglycemic activities of Disopyramide.
Darunavir Darunavir The therapeutic efficacy of Disopyramide can be decreased when used in combination with Darunavir.
Pemetrexed Injection Pemetrexed Injection Disopyramide may decrease the excretion rate of Pemetrexed which could result in a higher serum level.
Dimenhydrinate Dimenhydrinate The risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Disopyramide.
Lisdexamfetamine Lisdexamfetamine The risk or severity of Tachycardia can be increased when Disopyramide is combined with Lisdexamfetamine.
Nabilone Nabilone The risk or severity of Tachycardia and drowsiness can be increased when Disopyramide is combined with Nabilone.
Vorinostat Vorinostat The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Disopyramide.
Sorafenib Sorafenib The risk or severity of QTc prolongation can be increased when Sorafenib is combined with Disopyramide.
Sunitinib Sunitinib The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Disopyramide.
Dronabinol Dronabinol The risk or severity of Tachycardia and drowsiness can be increased when Disopyramide is combined with Dronabinol.
Lapatinib Lapatinib The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Disopyramide.
Levocetirizine Levocetirizine The risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Disopyramide.
Pegaptanib Injection Pegaptanib Injection Disopyramide may decrease the excretion rate of Pegaptanib which could result in a higher serum level.
Dasatinib Dasatinib The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Disopyramide.
Mexiletine Mexiletine Mexiletine may increase the arrhythmogenic activities of Disopyramide.
Armodafinil Armodafinil The metabolism of Disopyramide can be increased when combined with Armodafinil.
Azacitidine Injection Azacitidine Injection Disopyramide may decrease the excretion rate of Azacitidine which could result in a higher serum level.
Paclitaxel (with polyoxyethylated castor oil) Injection Paclitaxel (with polyoxyethylated castor oil) Injection The therapeutic efficacy of Castor oil can be decreased when used in combination with Disopyramide.
Temsirolimus Temsirolimus Temsirolimus may increase the QTc-prolonging activities of Disopyramide.
Lenalidomide Lenalidomide Disopyramide may decrease the excretion rate of Lenalidomide which could result in a higher serum level.
Nilotinib Nilotinib The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Nilotinib.
Toremifene Toremifene The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Toremifene.
Budesonide Budesonide The risk or severity of hyperglycemia can be increased when Budesonide is combined with Disopyramide.
Desmopressin Desmopressin Desmopressin may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Betaine Betaine The therapeutic efficacy of Disopyramide can be decreased when used in combination with Glycine betaine.
OnabotulinumtoxinA Injection OnabotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Disopyramide is combined with Botulinum toxin type A.
RimabotulinumtoxinB Injection RimabotulinumtoxinB Injection The risk or severity of adverse effects can be increased when Disopyramide is combined with Botulinum Toxin Type B.
Doripenem Injection Doripenem Injection Disopyramide may decrease the excretion rate of Doripenem which could result in a higher serum level.
Arsenic Trioxide Injection Arsenic Trioxide Injection The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Arsenic trioxide.
Desvenlafaxine Desvenlafaxine Disopyramide may increase the central nervous system depressant (CNS depressant) activities of Desvenlafaxine.
Cevimeline Cevimeline Cevimeline may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Nebivolol Nebivolol Disopyramide may increase the bradycardic activities of Nebivolol.
Bendamustine Injection Bendamustine Injection The metabolism of Bendamustine can be decreased when combined with Disopyramide.
Flecainide Flecainide Flecainide may increase the arrhythmogenic activities of Disopyramide.
Certolizumab Injection Certolizumab Injection The metabolism of Disopyramide can be increased when combined with Certolizumab pegol.
Ixabepilone Injection Ixabepilone Injection Ixabepilone may increase the QTc-prolonging activities of Disopyramide.
Daptomycin Injection Daptomycin Injection Daptomycin may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Praziquantel Praziquantel The metabolism of Praziquantel can be decreased when combined with Disopyramide.
Methylnaltrexone Injection Methylnaltrexone Injection Disopyramide may decrease the excretion rate of Methylnaltrexone which could result in a higher serum level.
Rufinamide Rufinamide Rufinamide may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Midazolam Midazolam Midazolam may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Naltrexone Injection Naltrexone Injection The risk or severity of adverse effects can be increased when Disopyramide is combined with Naltrexone.
Dexrazoxane Injection Dexrazoxane Injection Disopyramide may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.
Eltrombopag Eltrombopag The metabolism of Eltrombopag can be decreased when combined with Disopyramide.
Milnacipran Milnacipran Disopyramide may increase the central nervous system depressant (CNS depressant) activities of Milnacipran.
Plerixafor Injection Plerixafor Injection Disopyramide may decrease the excretion rate of Plerixafor which could result in a higher serum level.
Sodium Phosphate Sodium Phosphate The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Disopyramide.
Fesoterodine Fesoterodine Disopyramide may decrease the excretion rate of Fesoterodine which could result in a higher serum level.
Degarelix Injection Degarelix Injection The risk or severity of QTc prolongation can be increased when Degarelix is combined with Disopyramide.
Betaxolol Betaxolol Disopyramide may increase the bradycardic activities of Betaxolol.
Iloperidone Iloperidone The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Iloperidone.
Prasugrel Prasugrel Disopyramide may decrease the excretion rate of Prasugrel which could result in a higher serum level.
Lacosamide Lacosamide Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Everolimus Everolimus Everolimus may increase the QTc-prolonging activities of Disopyramide.
Tolvaptan (low blood sodium) Tolvaptan (low blood sodium) Tolvaptan may increase the excretion rate of Disopyramide which could result in a lower serum level and potentially a reduction in efficacy.
Dronedarone Dronedarone Disopyramide may increase the QTc-prolonging activities of Dronedarone.
AbobotulinumtoxinA Injection AbobotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Disopyramide is combined with Botulinum toxin type A.
Pralatrexate Injection Pralatrexate Injection Disopyramide may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Palonosetron Injection Palonosetron Injection Disopyramide may increase the central nervous system depressant (CNS depressant) activities of Palonosetron.
Saxagliptin Saxagliptin The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Saxagliptin.
Telavancin Injection Telavancin Injection The risk or severity of QTc prolongation can be increased when Telavancin is combined with Disopyramide.
Romidepsin Injection Romidepsin Injection The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Romidepsin.
Tapentadol Tapentadol The risk or severity of adverse effects can be increased when Tapentadol is combined with Disopyramide.
Topotecan Topotecan Disopyramide may decrease the excretion rate of Topotecan which could result in a higher serum level.
Golimumab Injection Golimumab Injection The metabolism of Disopyramide can be increased when combined with Golimumab.
Pazopanib Pazopanib The risk or severity of QTc prolongation can be increased when Pazopanib is combined with Disopyramide.
Asenapine Asenapine The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Asenapine.
Vigabatrin Vigabatrin Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Albendazole Albendazole The metabolism of Albendazole can be decreased when combined with Disopyramide.
Levonorgestrel Levonorgestrel The therapeutic efficacy of Disopyramide can be decreased when used in combination with Levonorgestrel.
Oxymorphone Oxymorphone The risk or severity of adverse effects can be increased when Oxymorphone is combined with Disopyramide.
Liraglutide Injection Liraglutide Injection The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Liraglutide.
Tocilizumab Injection Tocilizumab Injection The metabolism of Disopyramide can be increased when combined with Tocilizumab.
Dalfampridine Dalfampridine The serum concentration of Dalfampridine can be increased when it is combined with Disopyramide.
Fingolimod Fingolimod Fingolimod may increase the arrhythmogenic activities of Disopyramide.
Eribulin Injection Eribulin Injection The risk or severity of QTc prolongation can be increased when Eribulin is combined with Disopyramide.
IncobotulinumtoxinA Injection IncobotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Disopyramide is combined with Botulinum toxin type A.
Ceftaroline Injection Ceftaroline Injection Ceftaroline fosamil may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Lurasidone Lurasidone The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Disopyramide.
Acetaminophen Injection Acetaminophen Injection The metabolism of Acetaminophen can be decreased when combined with Disopyramide.
Vilazodone Vilazodone Vilazodone may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Ipilimumab Injection Ipilimumab Injection Disopyramide may decrease the excretion rate of Ipilimumab which could result in a higher serum level.
Denileukin Diftitox Injection Denileukin Diftitox Injection Aldesleukin may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Terbutaline Injection Terbutaline Injection The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Disopyramide.
Roflumilast Roflumilast Disopyramide may decrease the excretion rate of Roflumilast which could result in a higher serum level.
Linagliptin Linagliptin The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Linagliptin.
Rilpivirine Rilpivirine The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Disopyramide.
Abiraterone Abiraterone The serum concentration of Disopyramide can be increased when it is combined with Abiraterone.
Triptorelin Injection Triptorelin Injection The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Disopyramide.
Rivaroxaban Rivaroxaban Disopyramide may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.
Ruxolitinib Ruxolitinib Disopyramide may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.
Vandetanib Vandetanib The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Vandetanib.
Clobazam Clobazam Disopyramide may increase the central nervous system depressant (CNS depressant) activities of Clobazam.
Vemurafenib Vemurafenib The serum concentration of Disopyramide can be increased when it is combined with Vemurafenib.
Deferiprone Deferiprone Disopyramide may decrease the excretion rate of Deferiprone which could result in a higher serum level.
Axitinib Axitinib The metabolism of Axitinib can be decreased when combined with Disopyramide.
Crizotinib Crizotinib The risk or severity of QTc prolongation can be increased when Crizotinib is combined with Disopyramide.
Cabergoline Cabergoline Cabergoline may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Naloxone Injection Naloxone Injection Disopyramide may decrease the excretion rate of Naloxone which could result in a higher serum level.
Fondaparinux Injection Fondaparinux Injection Disopyramide may decrease the excretion rate of Fondaparinux which could result in a higher serum level.
Ezogabine Ezogabine Tiagabine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Enzalutamide Enzalutamide Disopyramide may decrease the excretion rate of Enzalutamide which could result in a higher serum level.
Mirabegron Mirabegron The risk or severity of urinary retention can be increased when Disopyramide is combined with Mirabegron.
Corticotropin, Repository Injection Corticotropin, Repository Injection The risk or severity of hyperglycemia can be increased when Corticotropin is combined with Disopyramide.
Linaclotide Linaclotide The therapeutic efficacy of Linaclotide can be decreased when used in combination with Disopyramide.
Teriflunomide Teriflunomide The serum concentration of Disopyramide can be decreased when it is combined with Teriflunomide.
Lorcaserin Lorcaserin The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Mecasermin.
Teduglutide Injection Teduglutide Injection Disopyramide may decrease the excretion rate of Teduglutide which could result in a higher serum level.
Bedaquiline Bedaquiline The risk or severity of QTc prolongation can be increased when Bedaquiline is combined with Disopyramide.
Alogliptin Alogliptin The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Alogliptin.
Pomalidomide Pomalidomide The metabolism of Pomalidomide can be decreased when combined with Disopyramide.
Canagliflozin Canagliflozin Canagliflozin may increase the hypoglycemic activities of Disopyramide.
Methazolamide Methazolamide Methazolamide may increase the excretion rate of Disopyramide which could result in a lower serum level and potentially a reduction in efficacy.
Dabrafenib Dabrafenib The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Disopyramide.
Trametinib Trametinib Disopyramide may decrease the excretion rate of Trametinib which could result in a higher serum level.
Levomilnacipran Levomilnacipran Disopyramide may increase the central nervous system depressant (CNS depressant) activities of Levomilnacipran.
Ertapenem Injection Ertapenem Injection Disopyramide may decrease the excretion rate of Ertapenem which could result in a higher serum level.
Vortioxetine Vortioxetine Disopyramide may increase the central nervous system depressant (CNS depressant) activities of Vortioxetine.
Perampanel Perampanel The metabolism of Perampanel can be decreased when combined with Disopyramide.
Ketorolac Injection Ketorolac Injection Ketorolac may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Simeprevir Simeprevir The metabolism of Disopyramide can be decreased when combined with Simeprevir.
Sofosbuvir Sofosbuvir Disopyramide may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.
Dapagliflozin Dapagliflozin Dapagliflozin may increase the hypoglycemic activities of Disopyramide.
Apremilast Apremilast The metabolism of Disopyramide can be increased when combined with Apremilast.
Droxidopa Droxidopa Disopyramide may decrease the excretion rate of Droxidopa which could result in a higher serum level.
Ceritinib Ceritinib The risk or severity of QTc prolongation can be increased when Ceritinib is combined with Disopyramide.
Siltuximab Injection Siltuximab Injection The metabolism of Disopyramide can be increased when combined with Siltuximab.
Albiglutide Injection Albiglutide Injection The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Albiglutide.
Eslicarbazepine Eslicarbazepine Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Belinostat Injection Belinostat Injection The metabolism of Disopyramide can be increased when combined with Belinostat.
Testosterone Injection Testosterone Injection Disopyramide may decrease the excretion rate of Testosterone which could result in a higher serum level.
Empagliflozin Empagliflozin The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Empagliflozin.
Hydrocodone Hydrocodone The risk or severity of adverse effects can be increased when Hydrocodone is combined with Disopyramide.
Suvorexant Suvorexant Suvorexant may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Dulaglutide Injection Dulaglutide Injection The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Dulaglutide.
Edoxaban Edoxaban Disopyramide may decrease the excretion rate of Edoxaban which could result in a higher serum level.
Peginterferon Beta-1a Injection Peginterferon Beta-1a Injection The metabolism of Disopyramide can be decreased when combined with Peginterferon beta-1a.
Methamphetamine Methamphetamine Disopyramide may increase the central nervous system depressant (CNS depressant) activities of Metamfetamine.
Tasimelteon Tasimelteon The metabolism of Tasimelteon can be decreased when combined with Disopyramide.
Lanreotide Injection Lanreotide Injection The therapeutic efficacy of Disopyramide can be decreased when used in combination with Lanreotide.
Pirfenidone Pirfenidone The metabolism of Pirfenidone can be decreased when combined with Disopyramide.
Secukinumab Injection Secukinumab Injection The metabolism of Disopyramide can be increased when combined with Secukinumab.
Risperidone Injection Risperidone Injection The risk or severity of QTc prolongation can be increased when Risperidone is combined with Disopyramide.
Insulin Human Inhalation Insulin Human Inhalation The risk or severity of hypoglycemia can be increased when Insulin human is combined with Disopyramide.
Lenvatinib Lenvatinib The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Disopyramide.
Panobinostat Panobinostat The risk or severity of QTc prolongation can be increased when Panobinostat is combined with Disopyramide.
Haloperidol Injection Haloperidol Injection The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Disopyramide.
Ivabradine Ivabradine The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Ivabradine.
Amiloride Amiloride Amiloride may increase the excretion rate of Disopyramide which could result in a lower serum level and potentially a reduction in efficacy.
Macitentan Macitentan Disopyramide may decrease the excretion rate of Macitentan which could result in a higher serum level.
Flibanserin Flibanserin Flibanserin may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Prednisolone Prednisolone The risk or severity of hyperglycemia can be increased when Prednisolone is combined with Disopyramide.
Brexpiprazole Brexpiprazole The therapeutic efficacy of Disopyramide can be decreased when used in combination with Brexpiprazole.
Ziprasidone Injection Ziprasidone Injection The risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Disopyramide.
Cariprazine Cariprazine Cariprazine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Penicillin G Procaine Injection Penicillin G Procaine Injection Disopyramide may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.
Eluxadoline Eluxadoline The risk or severity of constipation can be increased when Disopyramide is combined with Eluxadoline.
Insulin Degludec (rDNA Origin) Injection Insulin Degludec (rDNA Origin) Injection The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Insulin degludec.
Osimertinib Osimertinib The serum concentration of Disopyramide can be decreased when it is combined with Osimertinib.
Ixazomib Ixazomib Disopyramide may decrease the excretion rate of Ixazomib which could result in a higher serum level.
Lesinurad Lesinurad Disopyramide may decrease the excretion rate of Lesinurad which could result in a higher serum level.
Amphotericin B Liposomal Injection Amphotericin B Liposomal Injection Amphotericin B may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Dexamethasone Injection Dexamethasone Injection The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Disopyramide.
Brivaracetam Injection Brivaracetam Injection Brivaracetam may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Midodrine Midodrine The risk or severity of Tachycardia can be increased when Midodrine is combined with Disopyramide.
Pimavanserin Pimavanserin Pimavanserin may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Obeticholic Acid Obeticholic Acid The metabolism of Disopyramide can be decreased when combined with Obeticholic acid.
Diphenhydramine Injection Diphenhydramine Injection The risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Disopyramide.
Furosemide Injection Furosemide Injection The therapeutic efficacy of Disopyramide can be increased when used in combination with Furosemide.
Rucaparib Rucaparib The metabolism of Rucaparib can be decreased when combined with Disopyramide.
Lixisenatide Injection Lixisenatide Injection The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Lixisenatide.
Ribociclib Ribociclib The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Ribociclib.
Doxepin (Insomnia) Doxepin (Insomnia) Doxepin may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Plecanatide Plecanatide The therapeutic efficacy of Plecanatide can be decreased when used in combination with Disopyramide.
Deutetrabenazine Deutetrabenazine The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Deutetrabenazine.
Valbenazine Valbenazine Disopyramide may decrease the excretion rate of Valbenazine which could result in a higher serum level.
Deflazacort Deflazacort The risk or severity of hyperglycemia can be increased when Deflazacort is combined with Disopyramide.
Safinamide Safinamide The metabolism of Disopyramide can be decreased when combined with Safinamide.
Naldemedine Naldemedine Disopyramide may decrease the excretion rate of Naldemedine which could result in a higher serum level.
Midostaurin Midostaurin The metabolism of Disopyramide can be decreased when combined with Midostaurin.
Enasidenib Enasidenib The metabolism of Disopyramide can be decreased when combined with Enasidenib.
Benznidazole Benznidazole Disopyramide may decrease the excretion rate of Benznidazole which could result in a higher serum level.
Delafloxacin Delafloxacin The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Disopyramide.
Semaglutide Injection Semaglutide Injection The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Semaglutide.
Tetrabenazine Tetrabenazine The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Tetrabenazine.
Ertugliflozin Ertugliflozin The therapeutic efficacy of Disopyramide can be increased when used in combination with Ertugliflozin.
Buprenorphine Injection Buprenorphine Injection The risk or severity of adverse effects can be increased when Buprenorphine is combined with Disopyramide.
Apalutamide Apalutamide Disopyramide may decrease the excretion rate of Apalutamide which could result in a higher serum level.
Baricitinib Baricitinib Disopyramide may decrease the excretion rate of Baricitinib which could result in a higher serum level.
Lofexidine Lofexidine The risk or severity of QTc prolongation can be increased when Lofexidine is combined with Disopyramide.
Plazomicin Injection Plazomicin Injection Disopyramide may decrease the excretion rate of Plazomicin which could result in a higher serum level.
Eliglustat Eliglustat The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Eliglustat.
Encorafenib Encorafenib The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Disopyramide.
Binimetinib Binimetinib The metabolism of Binimetinib can be decreased when combined with Disopyramide.
Ivosidenib Ivosidenib The risk or severity of QTc prolongation can be increased when Ivosidenib is combined with Disopyramide.
Cannabidiol Cannabidiol The risk or severity of Tachycardia and drowsiness can be increased when Disopyramide is combined with Cannabidiol.
Stiripentol Stiripentol The metabolism of Disopyramide can be decreased when combined with Stiripentol.
Gilteritinib Gilteritinib The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Disopyramide.
Glasdegib Glasdegib The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Glasdegib.
Rifamycin Rifamycin The metabolism of Disopyramide can be decreased when combined with Rifamycin.
Prucalopride Prucalopride Disopyramide may decrease the excretion rate of Prucalopride which could result in a higher serum level.
Magnesium Citrate Magnesium Citrate The therapeutic efficacy of Magnesium citrate can be decreased when used in combination with Disopyramide.
Emapalumab-lzsg Injection Emapalumab-lzsg Injection The metabolism of Disopyramide can be increased when combined with Emapalumab.
Acyclovir Ophthalmic Acyclovir Ophthalmic Acyclovir may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Brexanolone Injection Brexanolone Injection Brexanolone may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Solriamfetol Solriamfetol The risk or severity of Tachycardia can be increased when Solriamfetol is combined with Disopyramide.
Triclabendazole Triclabendazole The risk or severity of QTc prolongation can be increased when Triclabendazole is combined with Disopyramide.
Entrectinib Entrectinib The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Entrectinib.
Istradefylline Istradefylline The metabolism of Istradefylline can be decreased when combined with Disopyramide.
Pitolisant Pitolisant The serum concentration of Disopyramide can be decreased when it is combined with Pitolisant.
Lefamulin Lefamulin Lefamulin may increase the QTc-prolonging activities of Disopyramide.
Phenytoin Injection Phenytoin Injection The serum concentration of Disopyramide can be decreased when it is combined with Phenytoin.
Fosphenytoin Injection Fosphenytoin Injection The serum concentration of Disopyramide can be decreased when it is combined with Fosphenytoin.
Lumateperone Lumateperone Lumateperone may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Lasmiditan Lasmiditan Lasmiditan may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Cenobamate Cenobamate The serum concentration of Disopyramide can be decreased when it is combined with Cenobamate.
Teprotumumab-trbw Injection Teprotumumab-trbw Injection The therapeutic efficacy of Disopyramide can be decreased when used in combination with Teprotumumab.
Selumetinib Selumetinib The metabolism of Selumetinib can be decreased when combined with Disopyramide.
Tucatinib Tucatinib The metabolism of Tucatinib can be decreased when combined with Disopyramide.
Capmatinib Capmatinib The metabolism of Disopyramide can be decreased when combined with Capmatinib.
Lemborexant Lemborexant Lemborexant may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Fenfluramine Fenfluramine Fenfluramine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Fostemsavir Fostemsavir The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Disopyramide.
Octreotide Octreotide The therapeutic efficacy of Disopyramide can be decreased when used in combination with Octreotide.
Satralizumab-mwge Injection Satralizumab-mwge Injection The serum concentration of Disopyramide can be decreased when it is combined with Satralizumab.
Relugolix Relugolix The risk or severity of QTc prolongation can be increased when Relugolix is combined with Disopyramide.
Progestin-Only (drospirenone) Oral Contraceptives Progestin-Only (drospirenone) Oral Contraceptives The therapeutic efficacy of Disopyramide can be decreased when used in combination with Drospirenone.
Viloxazine Viloxazine Disopyramide may increase the central nervous system depressant (CNS depressant) activities of Viloxazine.
Tobramycin Injection Tobramycin Injection Tobramycin may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Theophylline Theophylline The metabolism of Disopyramide can be decreased when combined with Theophylline.
Fenoprofen Fenoprofen Fenoprofen may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Indomethacin Indomethacin Indomethacin may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Mefenamic Acid Mefenamic Acid Mefenamic acid may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Naproxen Naproxen Naproxen may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Tolmetin Tolmetin Tolmetin may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Sulindac Sulindac Sulindac may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Trazodone Trazodone The risk or severity of QTc prolongation can be increased when Trazodone is combined with Disopyramide.
Isotretinoin Isotretinoin Disopyramide may decrease the excretion rate of Isotretinoin which could result in a higher serum level.
Sucralfate Sucralfate Disopyramide may decrease the excretion rate of Sucralfate which could result in a higher serum level.
Floxuridine Floxuridine Disopyramide may decrease the excretion rate of Floxuridine which could result in a higher serum level.
Phenobarbital Phenobarbital Phenobarbital may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Metaxalone Metaxalone Metaxalone may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Methotrexate Injection Methotrexate Injection Methotrexate may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Levorphanol Levorphanol The risk or severity of adverse effects can be increased when Levorphanol is combined with Disopyramide.
Primidone Primidone The metabolism of Disopyramide can be increased when combined with Primidone.
Methsuximide Methsuximide Methsuximide may increase the arrhythmogenic activities of Disopyramide.
Diethylpropion Diethylpropion Diethylpropion may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Chlorpromazine Chlorpromazine The risk or severity of QTc prolongation can be increased when Chlorpromazine is combined with Disopyramide.
Diazepam Diazepam Disopyramide may increase the central nervous system depressant (CNS depressant) activities of Diazepam.
Oxazepam Oxazepam Oxazepam may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Flurazepam Flurazepam Flurazepam may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Clorazepate Clorazepate Clorazepic acid may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Lorazepam Lorazepam Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Carmustine Carmustine The metabolism of Disopyramide can be decreased when combined with Carmustine.
Amantadine Amantadine The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Amantadine.
Codeine Codeine The risk or severity of adverse effects can be increased when Disopyramide is combined with Codeine.
Meprobamate Meprobamate Meprobamate may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Chlordiazepoxide Chlordiazepoxide Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Bromocriptine Bromocriptine The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Bromocriptine.
Metaproterenol Metaproterenol The risk or severity of Tachycardia can be increased when Disopyramide is combined with Orciprenaline.
Tranylcypromine Tranylcypromine The metabolism of Disopyramide can be decreased when combined with Tranylcypromine.
Phenelzine Phenelzine Disopyramide may increase the central nervous system depressant (CNS depressant) activities of Phenelzine.
Procarbazine Procarbazine Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Ergoloid Mesylates Ergoloid Mesylates Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Tetracycline Tetracycline Disopyramide may decrease the excretion rate of Tetracycline which could result in a higher serum level.
Prochlorperazine Prochlorperazine The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Disopyramide.
Thioridazine Thioridazine The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Thioridazine.
Trifluoperazine Trifluoperazine The metabolism of Trifluoperazine can be decreased when combined with Disopyramide.
Bleomycin Bleomycin Disopyramide may decrease the excretion rate of Bleomycin which could result in a higher serum level.
Sulfadiazine Sulfadiazine The therapeutic efficacy of Disopyramide can be increased when used in combination with Sulfadiazine.
Oxycodone Oxycodone The risk or severity of adverse effects can be increased when Oxycodone is combined with Disopyramide.
Methadone Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Disopyramide.
Oxybutynin Oxybutynin The risk or severity of adverse effects can be increased when Disopyramide is combined with Oxybutynin.
Benztropine Benztropine The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Disopyramide.
Maprotiline Maprotiline The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Disopyramide.
Ibuprofen Ibuprofen Ibuprofen may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Trihexyphenidyl Trihexyphenidyl The risk or severity of adverse effects can be increased when Disopyramide is combined with Trihexyphenidyl.
Orphenadrine Orphenadrine The risk or severity of QTc prolongation can be increased when Orphenadrine is combined with Disopyramide.
Perphenazine Perphenazine The metabolism of Perphenazine can be decreased when combined with Disopyramide.
Azathioprine Azathioprine The metabolism of Azathioprine can be decreased when combined with Disopyramide.
Fluphenazine Fluphenazine Fluphenazine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Phentermine Phentermine The therapeutic efficacy of Disopyramide can be increased when used in combination with Phentermine.
Methylphenidate Methylphenidate Disopyramide may decrease the excretion rate of Methylphenidate which could result in a higher serum level.
Amoxapine Amoxapine The risk or severity of QTc prolongation can be increased when Amoxapine is combined with Disopyramide.
Sulfasalazine Sulfasalazine Sulfasalazine may increase the hypoglycemic activities of Disopyramide.
Hydrocortisone Hydrocortisone The risk or severity of hyperglycemia can be increased when Hydrocortisone is combined with Disopyramide.
Cytarabine Cytarabine The risk or severity of adverse effects can be increased when Disopyramide is combined with Cytarabine.
Mechlorethamine Mechlorethamine The therapeutic efficacy of Disopyramide can be decreased when used in combination with Mechlorethamine.
Pyridostigmine Pyridostigmine The therapeutic efficacy of Disopyramide can be decreased when used in combination with Pyridostigmine.
Phenazopyridine Phenazopyridine Phenazopyridine may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Carbamazepine Carbamazepine The metabolism of Disopyramide can be increased when combined with Carbamazepine.
Molindone Molindone Molindone may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Methyldopa Methyldopa Disopyramide may decrease the excretion rate of Methyldopa which could result in a higher serum level.
Clonidine Clonidine The metabolism of Clonidine can be decreased when combined with Disopyramide.
Prazosin Prazosin The serum concentration of Prazosin can be increased when it is combined with Disopyramide.
Hydralazine Hydralazine Disopyramide may decrease the excretion rate of Hydralazine which could result in a higher serum level.
Cimetidine Cimetidine The serum concentration of Cimetidine can be increased when it is combined with Disopyramide.
Gentamicin Injection Gentamicin Injection Gentamicin may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Warfarin Warfarin Disopyramide may decrease the excretion rate of Warfarin which could result in a higher serum level.
Clonazepam Clonazepam Clonazepam may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Loperamide Loperamide Loperamide may increase the arrhythmogenic activities of Disopyramide.
Promethazine Promethazine The risk or severity of QTc prolongation can be increased when Promethazine is combined with Disopyramide.
Meclofenamate Meclofenamate Meclofenamic acid may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Nitrofurantoin Nitrofurantoin Disopyramide may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.
Griseofulvin Griseofulvin The metabolism of Disopyramide can be increased when combined with Griseofulvin.
Digoxin Digoxin Digoxin may increase the arrhythmogenic activities of Disopyramide.
Loxapine Loxapine Loxapine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Chloroquine Chloroquine The risk or severity of QTc prolongation can be increased when Chloroquine is combined with Disopyramide.
Quinine Quinine The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Quinine.
Ethosuximide Ethosuximide Ethosuximide may increase the arrhythmogenic activities of Disopyramide.
Triamterene Triamterene The metabolism of Triamterene can be decreased when combined with Disopyramide.
Lactulose Lactulose The therapeutic efficacy of Lactulose can be decreased when used in combination with Disopyramide.
Chlorothiazide Chlorothiazide The therapeutic efficacy of Disopyramide can be decreased when used in combination with Chlorothiazide.
Chlorthalidone Chlorthalidone The therapeutic efficacy of Disopyramide can be decreased when used in combination with Chlorthalidone.
Metolazone Metolazone The therapeutic efficacy of Disopyramide can be decreased when used in combination with Metolazone.
Isosorbide Isosorbide Isosorbide may increase the excretion rate of Disopyramide which could result in a lower serum level and potentially a reduction in efficacy.
Clindamycin Injection Clindamycin Injection Clindamycin may increase the QTc-prolonging activities of Disopyramide.
Secobarbital Secobarbital Disopyramide may increase the central nervous system depressant (CNS depressant) activities of Secobarbital.
Desipramine Desipramine Desipramine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Amitriptyline Amitriptyline The risk or severity of QTc prolongation can be increased when Amitriptyline is combined with Disopyramide.
Imipramine Imipramine The risk or severity of QTc prolongation can be increased when Imipramine is combined with Disopyramide.
Probenecid Probenecid The therapeutic efficacy of Disopyramide can be increased when used in combination with Probenecid.
Quinidine Quinidine Disopyramide may increase the arrhythmogenic activities of Quinidine.
Procainamide Procainamide Disopyramide may increase the arrhythmogenic activities of Procainamide.
Isoniazid Isoniazid The metabolism of Isoniazid can be decreased when combined with Disopyramide.
Pyrazinamide Pyrazinamide Disopyramide may decrease the excretion rate of Pyrazinamide which could result in a higher serum level.
Rifampin Rifampin The metabolism of Disopyramide can be increased when combined with Rifampicin.
Valproic Acid Valproic Acid The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Valproic acid.
Tamoxifen Tamoxifen The risk or severity of QTc prolongation can be increased when Tamoxifen is combined with Disopyramide.
Butabarbital Butabarbital Butabarbital may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Levothyroxine Levothyroxine The therapeutic efficacy of Disopyramide can be decreased when used in combination with Levothyroxine.
Liothyronine Liothyronine The therapeutic efficacy of Disopyramide can be decreased when used in combination with Liothyronine.
Methimazole Methimazole The metabolism of Disopyramide can be decreased when combined with Methimazole.
Chlorpropamide Chlorpropamide The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Chlorpropamide.
Glucagon Injection Glucagon Injection Disopyramide may increase the gastrointestinal motility reducing activities of Glucagon.
Tolbutamide Tolbutamide The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Tolbutamide.
Tolazamide Tolazamide The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Tolazamide.
Dextromethorphan Dextromethorphan Dextromethorphan may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Cyclobenzaprine Cyclobenzaprine The metabolism of Cyclobenzaprine can be decreased when combined with Disopyramide.
Niacin Niacin The therapeutic efficacy of Disopyramide can be decreased when used in combination with Niacin.
Baclofen Baclofen The therapeutic efficacy of Disopyramide can be decreased when used in combination with Baclofen.
Doxylamine Doxylamine The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Disopyramide.
Cyproheptadine Cyproheptadine The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Disopyramide.
Clemastine Clemastine The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Clemastine.
Chlorpheniramine Chlorpheniramine The risk or severity of QTc prolongation can be increased when Chlorpheniramine is combined with Disopyramide.
Brompheniramine Brompheniramine The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Disopyramide.
Meclizine Meclizine Meclizine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Ethambutol Ethambutol Disopyramide may decrease the excretion rate of Ethambutol which could result in a higher serum level.
Methyclothiazide Methyclothiazide The therapeutic efficacy of Disopyramide can be decreased when used in combination with Methyclothiazide.
Hydrochlorothiazide Hydrochlorothiazide The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Disopyramide.
Dantrolene Dantrolene Dantrolene may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Chlorzoxazone Chlorzoxazone The metabolism of Chlorzoxazone can be decreased when combined with Disopyramide.
Carisoprodol Carisoprodol Carisoprodol may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Methocarbamol Methocarbamol Methocarbamol may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Pyridoxine Pyridoxine Pyridoxine may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Folic Acid Folic Acid Folic acid may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Danazol Danazol The therapeutic efficacy of Disopyramide can be decreased when used in combination with Danazol.
Disulfiram Disulfiram The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Disopyramide.
Propranolol (Cardiovascular) Propranolol (Cardiovascular) Disopyramide may increase the bradycardic activities of Propranolol.
Pseudoephedrine Pseudoephedrine The therapeutic efficacy of Disopyramide can be decreased when used in combination with Pseudoephedrine.
Nortriptyline Nortriptyline The risk or severity of QTc prolongation can be increased when Nortriptyline is combined with Disopyramide.
Spironolactone Spironolactone Spironolactone may increase the excretion rate of Disopyramide which could result in a lower serum level and potentially a reduction in efficacy.
Amphotericin B Injection Amphotericin B Injection Amphotericin B may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Phytonadione Phytonadione Disopyramide may decrease the excretion rate of Phylloquinone which could result in a higher serum level.
Amikacin Injection Amikacin Injection Amikacin may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Nadolol Nadolol Disopyramide may increase the bradycardic activities of Nadolol.
Butorphanol Injection Butorphanol Injection The risk or severity of adverse effects can be increased when Butorphanol is combined with Disopyramide.
Nalbuphine Injection Nalbuphine Injection The risk or severity of adverse effects can be increased when Nalbuphine is combined with Disopyramide.
Allopurinol Allopurinol Disopyramide may decrease the excretion rate of Allopurinol which could result in a higher serum level.
Oxytocin Injection Oxytocin Injection The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Disopyramide.
Fluoxymesterone Fluoxymesterone Fluoxymesterone may increase the hypoglycemic activities of Disopyramide.
Trimethobenzamide Trimethobenzamide Trimethobenzamide may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Flavoxate Flavoxate Disopyramide may decrease the excretion rate of Flavoxate which could result in a higher serum level.
Papaverine Papaverine The risk or severity of QTc prolongation can be increased when Papaverine is combined with Disopyramide.
Fluorouracil Injection Fluorouracil Injection The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Disopyramide.
Colchicine Colchicine Disopyramide may decrease the excretion rate of Colchicine which could result in a higher serum level.
Cefaclor Cefaclor Cefaclor may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Cefadroxil Cefadroxil Cefadroxil may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Cefazolin Injection Cefazolin Injection Cefazolin may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Cephalexin Cephalexin Cephalexin may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Cefoxitin Injection Cefoxitin Injection Cefoxitin may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Dacarbazine Dacarbazine The metabolism of Dacarbazine can be decreased when combined with Disopyramide.
Acetazolamide Acetazolamide The therapeutic efficacy of Disopyramide can be increased when used in combination with Acetazolamide.
Cefotaxime Injection Cefotaxime Injection Cefotaxime may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Calcitonin Salmon Injection Calcitonin Salmon Injection Salmon calcitonin may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Ketoconazole Ketoconazole The risk or severity of QTc prolongation can be increased when Ketoconazole is combined with Disopyramide.
Pyrantel Pyrantel Pyrantel may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Thiotepa Injection Thiotepa Injection The therapeutic efficacy of Disopyramide can be decreased when used in combination with Thiotepa.
Isoxsuprine Isoxsuprine The risk or severity of Tachycardia can be increased when Disopyramide is combined with Isoxsuprine.
Ethacrynic Acid Ethacrynic Acid The therapeutic efficacy of Disopyramide can be decreased when used in combination with Etacrynic acid.
Colistimethate Injection Colistimethate Injection Colistimethate may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Metoprolol Metoprolol Disopyramide may increase the bradycardic activities of Metoprolol.
Hydroxyzine Hydroxyzine The risk or severity of QTc prolongation can be increased when Hydroxyzine is combined with Disopyramide.
Thiothixene Thiothixene The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Disopyramide.
Aspirin Aspirin The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Disopyramide.
Salsalate Salsalate Salsalate may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Alprazolam Alprazolam Alprazolam may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Temazepam Temazepam Temazepam may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Triazolam Triazolam Triazolam may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Dicyclomine Dicyclomine Disopyramide may decrease the excretion rate of Dicyclomine which could result in a higher serum level.
Hyoscyamine Hyoscyamine Hyoscyamine may increase the arrhythmogenic activities of Disopyramide.
Propantheline Propantheline Disopyramide may decrease the excretion rate of Propantheline which could result in a higher serum level.
Trimethoprim Trimethoprim Disopyramide may decrease the excretion rate of Trimethoprim which could result in a higher serum level.
Diltiazem Diltiazem Diltiazem may increase the arrhythmogenic activities of Disopyramide.
Nifedipine Nifedipine Nifedipine may increase the arrhythmogenic activities of Disopyramide.
Timolol Timolol Disopyramide may increase the bradycardic activities of Timolol.
Verapamil Verapamil The risk or severity of sinus node depression can be increased when Verapamil is combined with Disopyramide.
Atenolol Atenolol Disopyramide may increase the bradycardic activities of Atenolol.
Pindolol Pindolol Disopyramide may increase the bradycardic activities of Pindolol.
Cisplatin Injection Cisplatin Injection The serum concentration of Disopyramide can be increased when it is combined with Cisplatin.
Diflunisal Diflunisal Diflunisal may increase the hypoglycemic activities of Disopyramide.
Piroxicam Piroxicam Piroxicam may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Bumetanide Bumetanide The therapeutic efficacy of Disopyramide can be increased when used in combination with Bumetanide.
Streptozocin Streptozocin The metabolism of Disopyramide can be increased when combined with Streptozocin.
Etoposide Etoposide The metabolism of Etoposide can be decreased when combined with Disopyramide.
Glyburide Glyburide The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Glyburide.
Glipizide Glipizide The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Glipizide.
Indapamide Indapamide The risk or severity of QTc prolongation can be increased when Indapamide is combined with Disopyramide.
Amoxicillin Amoxicillin Disopyramide may decrease the excretion rate of Amoxicillin which could result in a higher serum level.
Nafcillin Injection Nafcillin Injection The metabolism of Disopyramide can be increased when combined with Nafcillin.
Oxacillin Injection Oxacillin Injection Disopyramide may decrease the excretion rate of Oxacillin which could result in a higher serum level.
Pentoxifylline Pentoxifylline The metabolism of Pentoxifylline can be decreased when combined with Disopyramide.
Pentamidine Injection Pentamidine Injection The risk or severity of QTc prolongation can be increased when Pentamidine is combined with Disopyramide.
Ceftriaxone Injection Ceftriaxone Injection Ceftriaxone may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Labetalol Labetalol Disopyramide may increase the bradycardic activities of Labetalol.
Auranofin Auranofin Disopyramide may decrease the excretion rate of Auranofin which could result in a higher serum level.
Leuprolide Injection Leuprolide Injection The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Disopyramide.
Gemfibrozil Gemfibrozil The metabolism of Disopyramide can be decreased when combined with Gemfibrozil.
Guanabenz Guanabenz The metabolism of Guanabenz can be decreased when combined with Disopyramide.
Dipivefrin Ophthalmic Dipivefrin Ophthalmic Adefovir dipivoxil may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Ceftazidime Injection Ceftazidime Injection Ceftazidime may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Ketoprofen Ketoprofen Ketoprofen may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Cefotetan Injection Cefotetan Injection Cefotetan may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Pimozide Pimozide The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Pimozide.
Flurbiprofen Flurbiprofen Flurbiprofen may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Amiodarone Amiodarone Amiodarone may increase the QTc-prolonging activities of Disopyramide.
Aztreonam Injection Aztreonam Injection Disopyramide may decrease the excretion rate of Aztreonam which could result in a higher serum level.
Buspirone Buspirone Disopyramide may decrease the excretion rate of Buspirone which could result in a higher serum level.
Ciprofloxacin Ciprofloxacin The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Disopyramide.
Mesalamine Mesalamine Mesalazine may increase the hypoglycemic activities of Disopyramide.
Diclofenac Diclofenac Diclofenac may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Fluoxetine Fluoxetine The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Fluoxetine.
Nimodipine Nimodipine Nimodipine may increase the arrhythmogenic activities of Disopyramide.
Interferon Alfa-2b Injection Interferon Alfa-2b Injection The metabolism of Disopyramide can be decreased when combined with Interferon alfa-2b.
Clozapine Clozapine The risk or severity of QTc prolongation can be increased when Clozapine is combined with Disopyramide.
Estazolam Estazolam Estazolam may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Ofloxacin Ofloxacin The risk or severity of QTc prolongation can be increased when Ofloxacin is combined with Disopyramide.
Didanosine Didanosine Disopyramide may decrease the excretion rate of Didanosine which could result in a higher serum level.
Pentostatin Injection Pentostatin Injection Disopyramide may decrease the excretion rate of Pentostatin which could result in a higher serum level.
Clarithromycin Clarithromycin Clarithromycin may increase the QTc-prolonging activities of Disopyramide.
Benazepril Benazepril The risk or severity of hypoglycemia can be increased when Benazepril is combined with Disopyramide.
Etodolac Etodolac Etodolac may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Felodipine Felodipine Felodipine may increase the arrhythmogenic activities of Disopyramide.
Fosinopril Fosinopril Disopyramide may decrease the excretion rate of Fosinopril which could result in a higher serum level.
Nabumetone Nabumetone Nabumetone may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Amlodipine Amlodipine Amlodipine may increase the arrhythmogenic activities of Disopyramide.
Itraconazole Itraconazole The risk or severity of QTc prolongation can be increased when Itraconazole is combined with Disopyramide.
Lisinopril Lisinopril Disopyramide may decrease the excretion rate of Lisinopril which could result in a higher serum level.
Oxaprozin Oxaprozin Oxaprozin may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Sotalol Sotalol The risk or severity of hypoglycemia can be increased when Sotalol is combined with Disopyramide.
Bisoprolol Bisoprolol The therapeutic efficacy of Disopyramide can be increased when used in combination with Bisoprolol.
Zolpidem Zolpidem The metabolism of Zolpidem can be decreased when combined with Disopyramide.
Isradipine Isradipine Isradipine may increase the arrhythmogenic activities of Disopyramide.
Omeprazole Omeprazole The metabolism of Disopyramide can be increased when combined with Omeprazole.
Cisapride Cisapride The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Cisapride.
Gabapentin Gabapentin Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Venlafaxine Venlafaxine The risk or severity of QTc prolongation can be increased when Venlafaxine is combined with Disopyramide.
Nizatidine Nizatidine The therapeutic efficacy of Disopyramide can be decreased when used in combination with Nizatidine.
Fluvoxamine Fluvoxamine The metabolism of Disopyramide can be decreased when combined with Fluvoxamine.
Nefazodone Nefazodone The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Nefazodone.
Lamotrigine Lamotrigine Lamotrigine may increase the arrhythmogenic activities of Disopyramide.
Losartan Losartan Losartan may increase the arrhythmogenic activities of Disopyramide.
Valacyclovir Valacyclovir Valaciclovir may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Tramadol Tramadol The risk or severity of adverse effects can be increased when Tramadol is combined with Disopyramide.
Carboplatin Injection Carboplatin Injection Carboplatin may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Moexipril Moexipril The risk or severity of QTc prolongation can be increased when Moexipril is combined with Disopyramide.
Ifosfamide Injection Ifosfamide Injection Disopyramide may decrease the excretion rate of Ifosfamide which could result in a higher serum level.
Nicardipine Nicardipine Nicardipine may increase the arrhythmogenic activities of Disopyramide.
Bupropion Bupropion Bupropion may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Ticlopidine Ticlopidine The metabolism of Disopyramide can be decreased when combined with Ticlopidine.
Saquinavir Saquinavir The risk or severity of QTc prolongation can be increased when Saquinavir is combined with Disopyramide.
Metformin Metformin The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Metformin.
Nisoldipine Nisoldipine Disopyramide may increase the arrhythmogenic activities of Nisoldipine.
Lamivudine Lamivudine The serum concentration of Lamivudine can be increased when it is combined with Disopyramide.
Riluzole Riluzole The metabolism of Riluzole can be decreased when combined with Disopyramide.
Acarbose Acarbose The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Acarbose.
Glimepiride Glimepiride Glimepiride may increase the arrhythmogenic activities of Disopyramide.
Gemcitabine Injection Gemcitabine Injection Disopyramide may decrease the excretion rate of Gemcitabine which could result in a higher serum level.
Indinavir Indinavir The therapeutic efficacy of Disopyramide can be decreased when used in combination with Indinavir.
Ritonavir Ritonavir The serum concentration of Disopyramide can be increased when it is combined with Ritonavir.
Cidofovir Injection Cidofovir Injection Cidofovir may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Meropenem Injection Meropenem Injection Disopyramide may decrease the excretion rate of Meropenem which could result in a higher serum level.
Clomipramine Clomipramine The risk or severity of QTc prolongation can be increased when Clomipramine is combined with Disopyramide.
Zafirlukast Zafirlukast The metabolism of Disopyramide can be decreased when combined with Zafirlukast.
Fosfomycin Fosfomycin Disopyramide may decrease the excretion rate of Fosfomycin which could result in a higher serum level.
Mirtazapine Mirtazapine The risk or severity of QTc prolongation can be increased when Mirtazapine is combined with Disopyramide.
Topiramate Topiramate The risk or severity of hyperthermia and oligohydrosis can be increased when Disopyramide is combined with Topiramate.
Zileuton Zileuton The metabolism of Zileuton can be decreased when combined with Disopyramide.
Insulin Lispro Injection Insulin Lispro Injection The risk or severity of hypoglycemia can be increased when Insulin lispro is combined with Disopyramide.
Pramipexole Pramipexole The serum concentration of Pramipexole can be increased when it is combined with Disopyramide.
Donepezil Donepezil The therapeutic efficacy of Disopyramide can be decreased when used in combination with Donepezil.
Nelfinavir Nelfinavir The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Disopyramide.
Azithromycin Azithromycin The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Disopyramide.
Loratadine Loratadine Disopyramide may increase the anticholinergic activities of Loratadine.
Carvedilol Carvedilol Disopyramide may increase the bradycardic activities of Carvedilol.
Nilutamide Nilutamide Disopyramide may decrease the excretion rate of Nilutamide which could result in a higher serum level.
Flutamide Flutamide The metabolism of Flutamide can be decreased when combined with Disopyramide.
Selegiline Selegiline The metabolism of Disopyramide can be decreased when combined with Selegiline.
Sertraline Sertraline Sertraline may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Propafenone Propafenone Propafenone may increase the arrhythmogenic activities of Disopyramide.
Tamsulosin Tamsulosin The therapeutic efficacy of Tamsulosin can be increased when used in combination with Disopyramide.
Ropinirole Ropinirole Ropinirole may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Quetiapine Quetiapine The risk or severity of QTc prolongation can be increased when Quetiapine is combined with Disopyramide.
Cefepime Injection Cefepime Injection Cefepime may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Cefprozil Cefprozil Cefprozil may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Cefpodoxime Cefpodoxime Cefpodoxime may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Cetirizine Cetirizine The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Disopyramide.
Paroxetine Paroxetine Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Tolcapone Tolcapone Tolcapone may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Citalopram Citalopram The risk or severity of QTc prolongation can be increased when Citalopram is combined with Disopyramide.
Capecitabine Capecitabine Disopyramide may decrease the excretion rate of Capecitabine which could result in a higher serum level.
Efavirenz Efavirenz The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Disopyramide.
Abacavir Abacavir Disopyramide may decrease the excretion rate of Abacavir which could result in a higher serum level.
Pioglitazone Pioglitazone The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Pioglitazone.
Celecoxib Celecoxib The therapeutic efficacy of Disopyramide can be increased when used in combination with Celecoxib.
Rosiglitazone Rosiglitazone The metabolism of Disopyramide can be decreased when combined with Rosiglitazone.
Tolterodine Tolterodine The risk or severity of QTc prolongation can be increased when Tolterodine is combined with Disopyramide.
Thalidomide Thalidomide Thalidomide may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Oseltamivir Oseltamivir Oseltamivir may decrease the excretion rate of Disopyramide which could result in a higher serum level.
Balsalazide Balsalazide Balsalazide may increase the hypoglycemic activities of Disopyramide.
Nateglinide Nateglinide The risk or severity of hypoglycemia can be increased when Disopyramide is combined with Nateglinide.
Galantamine Galantamine The risk or severity of QTc prolongation can be increased when Galantamine is combined with Disopyramide.
Levetiracetam Levetiracetam Levetiracetam may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Rabeprazole Rabeprazole The metabolism of Rabeprazole can be increased when combined with Disopyramide.
Terbinafine Terbinafine The metabolism of Terbinafine can be decreased when combined with Disopyramide.

Content provided by: AHFS® Patient Medication Information™. © Copyright, 2021. The American Society of Health-System Pharmacists